MedTrace Logo

PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia

NCT02971982 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-11-23

No results posted yet for this study

Summary

Patients will receive RCD or PCD combination as induction treatment followed by rituximab or velcade maintenance therapy, as the investigators try to compare the, very good partial remission (VGPR) rate, complete remission (CR) rates, Overall remission rate (MR+CR + VGPR + partial remission (PR) rate), major reaction rate (MRR, PR+VGPR+CR) at the end of the research.

Conditions

  • Treatment

Interventions

DRUG

rituximab /Dexamethasone/cyclophosphamide

rituximab:375mg/m2 ,Dexamethasone 20mg q12h,cyclophosphamide 750mg

DRUG

Velcade/Dexamethasone/cyclophosphamide

Velcade:1.3mg/m2,Dexamethasone 10mg q12h,cyclophosphamide 750mg

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Fu cheng cheng, Phd · First Affiliated Hospital,Soochow University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2018-10-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02971982 on ClinicalTrials.gov